# Sutro Biopharma, Inc.

**STRO**

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001382101

**E**

**weakest fifth of 369 graded peers in healthcare**

rank 341 of 369; percentile 92.4; sampling error 2.5 points; lower is stronger

A B C D E

**E, the bear**




| Scoreboard | |
|---|---|
| **Profitability** | C/D<br>percentile 61.5 |
| **Solvency** | D/E<br>percentile 78.7 |
| **Growth and financing** | D<br>percentile 70.3 |
| **Reliability** | 0.87 AUC<br>filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025 |
| **Peer failure rate** | 1.03% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $120M to $591M assets<br>total assets $173.8M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | dilution, short runway, distress; fortre... |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Mar 23, 2026<br>222 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026 |
| **Last close** | $9.11<br>2026-10-30; market equity $151.1M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 23, 2026*

We are a clinical stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF®, and our site-specific conjugation platform, XpressCF+®. We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, and dual-payload ADCs, or dpADCs. Our molecules are directed primarily against clinically validated targets where the current standard of care is suboptimal.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 61.5** | | | | | | |
| Gross profitability | not computable | 32.4% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |
| Accruals ratio | (4.9%) | (6.6%) | 61.5 | 803 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 78.7** | | | | | | |
| Twelve-month failure probability | 1.27% | 0.07% | 89.0 | 246 | 2026-06-30 | |
| Altman Z double-prime | (22.06) | (0.35) | 75.4 | 748 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 2.01x | 2.92x | 71.6 | 829 | 2025-12-31 | |
| **Growth and financing, sleeve percentile 70.3** | | | | | | |
| Revenue growth, three-year compound | 14.8% | 10.1% | 39.9 | 412 | 2025-12-31 | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *four consecutive annual FCF observations are required; found 1* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *required facts have no common fiscal period end* | | | | | | |
| Asset growth, three years | (24.7%) | 2.2% | 88.6 | 696 | 2025-12-31 | |
| Net share issuance, one year | 97.8% | 2.5% | 82.4 | 631 | 2026-03-16 | |


## Warnings

*4 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Dilution | split-adjusted year-over-year share growth is 97.8% |
| Short runway | cash runway is 4.5 months |
| Distress | CHS probability 1.274001%; universe top-decile threshold 0.943958% |
| Fortress balance sheet | cash minus debt is 65,207,000 USD; Altman Z is not used |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 336 | Editas Medicine, Inc. (EDIT) | 91.0 | E | fortress balance sheet |
| 337 | Century Therapeutics, Inc. (IPSC) | 91.3 | E | dilution, fortress balance sheet |
| 338 | Beyond Air, Inc. (XAIR) | 91.6 | E | dilution, short runway, distress |
| 339 | Precision Biosciences Inc. (DTIL) | 91.8 | E | dilution, fortress balance sheet |
| 340 | Airsculpt Technologies, Inc. (AIRS) | 92.1 | E | late filer |
| 341 | Sutro Biopharma, Inc. (STRO) | 92.4 | E | dilution, short runway, distress, fortress balance sheet |
| 342 | Elutia Inc. (ELUT) | 92.7 | E | short runway, fortress balance sheet |
| 343 | China Pharma Holdings, Inc. (CPHI) | 92.9 | E | dilution, late filer |
| 344 | Celularity Inc. (CELU) | 93.2 | E | short runway, late filer |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | |
|---|---|---|---|---|
| 345 | Fortress Biotech, Inc. (FBIO) | 93.6 | E | fortress balance sheet |
| 346 | Fortress Biotech, Inc. (FBIOP) | 93.6 | E | fortress balance sheet |

## What the price implies

*at the 2026-10-30 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 133.1% | 7.3% | 92 |
| Distance from 52-week high | (77.8%) | (28.7%) | 11 |
| EBIT to enterprise value | (157.4%) | (1.4%) | 4 |
| Free cash flow yield | 7.4% | (1.0%) | 88 |
| Book value to price | (0.68) | 0.28 | 2 |
| Sales to price | 0.68 | 0.30 | 74 |
| Composite equity issuance, five years | 128.5% | 20.5% | 83 |
| Relative strength against the sector, log excess return | 0.63 | (0.14) | 92 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $54.3M |
| Operating cash flow, four quarters | -$145.2M |
| Months of runway | 4.5 |
| Days since last periodic filing | 80 (10-Q received Aug 12, 2026) |
| Median daily dollar volume, 63 sessions | $4.0M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | operating income | us-gaap:OperatingIncomeLoss | -$89.3M | 2023-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 2 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$88.6M | 2023-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 3 | income tax | us-gaap:IncomeTaxExpenseBenefit | $18.2M | 2023-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 4 | total debt | us-gaap:LongTermDebt | $4.1M | 2023-12-31 | 2024-03-25 | 10-K | 24-035949 |
| 5 | book equity | us-gaap:StockholdersEquity | $149.6M | 2023-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 6 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $69.3M | 2023-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 7 | total debt | us-gaap:LongTermDebt | $16.3M | 2022-12-31 | 2024-03-25 | 10-K | 24-035949 |
| 8 | book equity | us-gaap:StockholdersEquity | $217.0M | 2022-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $47.3M | 2022-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 10 | net income | us-gaap:NetIncomeLoss | -$191.1M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 11 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$177.2M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 12 | assets | us-gaap:Assets | $173.8M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 13 | assets | us-gaap:Assets | $387.2M | 2024-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 14 | current assets | us-gaap:AssetsCurrent | $150.9M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 15 | current liabilities | us-gaap:LiabilitiesCurrent | $75.1M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 16 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$978.0M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 17 | operating income | us-gaap:OperatingIncomeLoss | -$158.4M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 18 | book equity | us-gaap:StockholdersEquity | -$132.5M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 19 | liabilities | us-gaap:Liabilities | $306.3M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 20 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $6.8M | 2023-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 21 | operating income | us-gaap:OperatingIncomeLoss | -$37.2M | 2018-12-31 | 2021-03-18 | 10-K | 21-013945 |
| 22 | interest expense | us-gaap:InterestExpense | $1.6M | 2018-12-31 | 2019-04-01 | 10-K | 19-010253 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $102.5M | 2025-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 24 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $62.0M | 2024-12-31 | 2026-03-23 | 10-K | 26-119873 |
| 25 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $153.7M | 2023-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 26 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $67.8M | 2022-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 27 | assets | us-gaap:Assets | $470.7M | 2023-12-31 | 2025-03-13 | 10-K | 25-038884 |
| 28 | assets | us-gaap:Assets | $406.9M | 2022-12-31 | 2024-03-25 | 10-K | 24-035949 |
| 29 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 16,567,238 | 2026-03-16 | 2026-03-23 | 10-K | 26-119873 |
| 30 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 83,775,336 | 2025-03-06 | 2025-03-13 | 10-K | 25-038884 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.